Mustang Bio (NASDAQ:MBIO – Get Free Report) will likely be issuing its Q3 2026 results on Wednesday, November 18th. Analysts expect Mustang Bio to announce earnings of ($140.00) per share for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 7:00 AM ET.
Mustang Bio (NASDAQ:MBIO – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($140.00) by $139.86.
Mustang Bio Stock Performance
Shares of MBIO stock opened at $0.39 on Tuesday. Mustang Bio has a 1 year low of $0.35 and a 1 year high of $1.43. The stock’s 50 day simple moving average is $0.44 and its two-hundred day simple moving average is $0.66.
Analyst Ratings Changes
Check Out Our Latest Stock Analysis on Mustang Bio
Mustang Bio Company Profile
Mustang Bio is a U.S.-based biotechnology company focused on developing cell and gene therapies for cancer and rare genetic diseases. The company has been a subsidiary of Fortress Biotech and has operated primarily as a developer of investigational treatments rather than as a commercial drug company. Its research has included CAR T-cell therapies, which modify a patient’s immune cells to target cancer. Historical programs have included MB-106, directed at the CD20 protein found on certain B-cell cancers, and MB-101, an investigational therapy targeting IL13Rα2 in glioblastoma.
Featured Stories
- Five stocks we like better than Mustang Bio
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.
